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INTRODUCTION
Multiple myeloma is a malignancy of plasma cells (PC), the terminally differentiated, immunoglobulin-secreting B cells 1 . The primary, tumor-initiating genetic events include translocations and hyperdiploidy, while secondary events, such as activation of the oncogene MYC drive disease progression 2, 3 . Despite recent therapeutic advances and improved survival, myeloma remains an incurable malignancy with nearly all patients eventually succumbing to treatment-refractory disease, which often is highly proliferative 4 .
Recently, inhibitors targeting the acetyl-binding pockets of the bromodomains of the bromodomain and extra-terminal domain (BET) family of proteins BRD2-4 and BRDT were developed. BET proteins activate transcription through their ability to bind to acetyl-modified lysine residues of histone tails 5, 6 thereby serving as chromatin scaffolds that recruit the PTEFb and PAFc1 complexes to Polymerase II (RNA Pol II), ensuring transcriptional initiation and elongation [7] [8] [9] [10] [11] . Two classes of BET inhibitors, benzodiazepine and quinolines, have been
shown to have significant anti-proliferative activity against a variety of hematologic tumors 12 .
Specifically, the benzodiazepine JQ1 13 was shown to be active against myeloma 14 , lymphoma 15 and acute lymphoblastic leukemia 16 in vitro and in vivo, while of the quinoline class of BET protein inhibitors, I-BET151, was shown to have pre-clinical activity against acute leukemia, including MLL-related acute myeloid leukemia 10, 11 . At the mechanistic level, a unifying theme for both JQ1 and I-BET151 is their ability to inhibit transcription of MYC and MYC-dependent oncogenic programmes 11, 14, 15 . Oncogenic MYC activation and overexpression is common in myeloma 17, 18 and can come about by a variety of genetic mechanisms including chromosomal rearrangements that bring MYC transcriptional regulation under the influence of immunoglobulin gene regulatory areas, gene amplification or by oncogenic RAS-driven MYC overexpression 2, 19 .
Herein, by combining in vitro and in vivo approaches with global transcriptomics, we identify genes and biological processes that underpin the anti-myeloma activity of the tool molecule I-BET151. Further, we translate this knowledge to the structurally distinct clinical compound I-BET762 20 , which for the first time demonstrates that it displays significant anti-tumor activity in vivo, in an animal model of systemic myeloma.
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MATERIAL AND METHODS
Primary myeloma cells. Primary myeloma CD138
+ plasma cells were isolated in high purity (>98%, data not shown) from bone marrow (BM) samples, using CD138 microbeads and magnetic cell sorting (Miltenyi Biotec). The samples were taken at diagnosis or relapse of the disease, as part of the patients' clinical assessment at the Hammersmith Hospital after appropriate written informed consent was obtained in accordance with the Declaration of Helsinki. The study was approved by the Local Research Ethics Committee.
Cell culture and inhibitors. For in vitro cell proliferation and apoptosis assays, myeloma cell lines were cultured using RPMI 1640 medium supplemented with 10% fetal bovine serum (Sigma), 2mM L-Glutamine, penicillin 500IU/mL and streptomycin 500μg/mL. Cells were placed in 96-well U bottom plates at final concentration of 0.2x10 6 /mL in a humidified incubator with 5% CO 2 at 37 o C. For stroma versus non-stroma experiments, myeloma cells were placed in flat bottom 96-well plates with MS5 cells at >90% confluence or in wells without stroma. Compounds (i.e., I-BET151, I-BET762, the inactive isomer I-BET768 and JQ1) were serially diluted into media and added to the cultures at the indicated concentrations, starting from a 10mM dimethyl sulfoxide (DMSO) stock solution.
Primary myeloma cells were cultured in flat bottom 96-well plates in the presence of MS5 stroma cells, using complete medium as above, supplemented with interleukin-6 (IL-6) at 5ng/mL.
Gene expression profiling (GEP).
Total RNA was extracted from H929 and KMS12BM cells after culture with I-BET151 1μM or vehicle (DMSO) for 6 hours (n=3 independent experiments), using the RNeasy Mini kit (Qiagen). Genomic DNA contamination was eliminated using columns (Qiagen) and DNAase digestion. The extracted RNA was quantified in a Nanodrop, while purity and integrity was confirmed On an Agilent 2100
Bioanalyser with RNA Nano Chips. cDNA was produced from 150ng total RNA input, using the Ambion® WT Expression Kit. The cDNA was then fragmented and labelled using the GeneChip WT Terminal Labelling Kit (Affymetrix) and hybridised on Human Gene ST1.0
Arrays (Affymetrix) on a GeneChip Fluidics Station 450. The arrays were scanned in a GeneChip® Scanner 3000 7G with autoloader.
For gene set enrichment analysis (GSEA), core probes of Affymetrix HuGene_1_0-st array were used to summarise expressions at the transcript level. RMA 21 was applied for background correction using the antigenomic probes and quantile normalisation. R and Bioconductor package xps were used for data extraction. 
RESULTS
I-BET151 induces cell cycle arrest and apoptosis in myeloma cell lines
We used DNA content analysis to study the effect of I-BET151 on the cell cycle status of 6 myeloma cell lines (H929, KMS12PE, KMS12BM, KMS18, KMS11 and RPMI8226), representative of the most common translocations found in myeloma (Table 1) 19 . I-BET151 caused a significant dose-and time-dependent decrease in the proportion of myeloma cells in S/G2 phase at 24, 48 and 72 hours (Fig 1A and 1B) . The most pronounced effect was observed at 72 hours in all 6 myeloma cell lines, starting at 100nM (Suppl Fig 1A) . Dual Ki67/PI staining confirmed that the majority of live cells resided in the G0 phase after treatment with I-BET151 at 1μM for 72 hours (Fig 1C and Suppl Fig 1B) commensurate with a dose-and time-dependent decrease in cell proliferation (Fig 1D) and abrogation of BrdU incorporation (Fig 1E) .
Annexin-V staining also confirmed an increased proportion of events in apoptosis (Fig 1F) .
The delayed rather than immediate effects of I-BET151 on myeloma cell proliferation and survival, suggest that these effects are specific and not the result of non-specific cell toxicity.
We investigated the I-BET151 anti-myeloma activity on the MS5 stroma cell line conditions. We found that in 5/6 cell lines tested, I-BET151 IC50 was similar between stroma and stroma-free culture (p>0.05, IC50 range: 133nM-411nM), while in KMS11, IC50 increased from 88 to 186nM in the presence of stroma (p=0.002; Fig 1G) .
Activity of I-BET151 against primary myeloma cells in vitro and in xenotransplantation
Next, we determined the anti-myeloma activity of I-BET151 on CD138-selected, primary BM myeloma cells (n=4 patients) cultured on MS5 stroma, in the presence of IL-6 (5ng/mL). As in myeloma cell lines, there was a dose-dependent decrease in the proportion of cells in S/G2 phase and an increase of subG0 events, suggesting that myeloma cells were entering cell cycle arrest and undergoing apoptosis (Fig 2A-B) . In addition, in an in vivo model of subcutaneous myeloma, I-BET151-treated mice had 4-5-fold smaller myeloma tumors (p<0.001; Fig 2C) and a significantly reduced rate of tumor size doubling than vehicletreated mice (p<0.001; Fig 2D) . We conclude that I-BET151 has significant anti-myeloma activity in vitro and in vivo, even in the presence of stroma and pro-myeloma survival factors.
MYC-dependent and -independent molecular signatures of I-BET151 anti-myeloma activity
Much of the anti-proliferative effect of the BET domain inhibitors has been attributed to direct inhibition of transcription of MYC and consequently of the MYC-dependent transcriptional programme 11, 14, 15 . To investigate the molecular basis of I-BET151 anti-myeloma activity, we generated global RNA profile of the myeloma cell lines H929 and KMS12BM which carry
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We found that after treatment with I-BET151, among the top (imost upregulated) and bottom (most downregulated) 50 genes in the gene ranking metrics (Fig 3A) , only around 10% are overlapping between the two cell lines (Fig 3B) , probably reflecting their distinct oncogenic programmes and genetic profiles.
In agreement with previous data, 11, 14, 15 MYC was amongst the 20 most downregulated genes in KMS12BM cells (Fig 3A and B Fig 2B) .
Since not all tumor cells with MYC overexpression are sensitive to BET inhibitors and MYC expression is not always downregulated by BET domain inhibition 10, 11 , alternative, MYCindependent mechanisms could also underpin the observed anti-proliferative effect. We identified a number of MYC-dependent but also a much larger number of MYC-independent molecular signatures that were enriched in both or either cell lines (Fig 3D and Suppl Table   1 ). These included a geneset representing genes previously downregulated in myeloma cell lines treated with the HDAC inhibitor Trichostatin 25 (Fig 3E) , a finding previously reported in GEP studies involving JQ1
15
. IRF4-dependent signature was downregulated in KMS12BM (Fig 3E and Suppl Table 1 ). IRF4 is a TF critical for normal plasma cell development 26 , but also drives a myeloma-specific transcriptional programme indispensable for cell survival 27 .
I-BET151 inhibits transcription of oncogenic MYC by interfering with its BRD4-dependent transcriptional activation
To explore the transcriptional events in MYC downregulation, we used OPM-2 myeloma cells, characterised by MYC overexpression due to a translocation that brings MYC under the transcriptional control of IgH gene enhancers 28, 29 . As for the other myeloma cell lines, I-BET151 caused a time-and dose-dependent inhibition of OPM-2 cell proliferation (Fig 4A) with commensurate reduction in MYC mRNA expression (Fig 4B and C) . Next we studied the in cis and trans changes at the IgH1 enhancer that drives MYC over-expression in OPM-9 testis and ovary), RNA Pol II, P-TEFb and PAF complexes. We found that upon treatment with I-BET151, BRD2, 3 and 4 occupancy decreased in a time-dependent manner as early as 2hr post-treatment (Fig 4D) . Similarly, recruitment of CDK9 and PAF, critical components of the P-TEFb and PAFc1 complexes respectively, as well as binding of RNA Pol II to the IgH1 gene enhancer, were almost abolished (Fig 4E) . We conclude that I-BET151-mediated transcriptional silencing of MYC in myeloma cells involves inhibition of BRD2-4 binding, failure to recruit P-TEFb and PAFc1 complexes to the IgH1 enhancer by BRD2-4 and lack of RNA Pol II recruitment.
Dynamics of I-BET151-induced transcription of HEXIM1
Our GEP analysis showed that HEXIM1, a negative regulator of P-TEFb 30-32 was one of the most upregulated genes in both cell lines after treatment with I-BET151 (Fig 3A) , as confirmed with RQ-PCR (Fig 5A) . Interestingly, HEXIM1 is also within the top 10 most upregulated genes in lymphoma and myeloma cell lines (different to those reported here) treated with JQ1 14, 15 , suggesting that HEXIM1 upregulation is a consistent feature of BET protein inhibitors. While HEXIM1 mRNA levels increased as early as 3 hrs post I-BET151 treatment, increased HEXIM1 protein levels were first detected in H929 cells at 6hrs posttreatment (Fig 5B and C) . A similar pattern was seen in OPM2 and KMS12BM cells (Suppl Fig 3A) .
As the main function of HEXIM1 is to sequester and inactivate P-TEFb (i.e., CDK9 and cyclin T1), we analysed the relative amount of inactive and active P-TEFb fractions. Using a previously validated methodology 33,34 (and Suppl Fig 3) , we assessed the relative amounts of HEXIM1-bound inactive and HEXIM1-free active CDK9 in the low and high salt cell extracts respectively by immunoblotting following treatment with I-BET151 (Fig 5C and   Suppl Fig 3B) .
Overall, we found that in H929 cells, after a temporary increase, active CDK9 eventually decreased to levels lower than baseline (Fig 5C) in the first 24 hrs following treatment with I-BET151. By contrast, a decrease in the levels of active CDK9 in OPM2 cells was only observed beyond 48hrs, when apoptosis and cell cycle arrest were first observed (Suppl Fig   3) . These findings suggest that, at least in the case of H929 cells, increased HEXIM1
expression in response to I-BET treatment is associated with reduced availability of active CDK9 and consequently reduced availability of P-TEFb to participate in active transcription.
To investigate the role of BRD2-4 in HEXIM1 transcription in response to I-BET151 we performed ChIP analysis of BRD2-4 binding at the promoter of HEXIM1 at the same time in the same OPM2 cells in which I-BET151 induced abrogation of BRD2-4 binding at the IgH1 enhancer (Fig 3) . We found enrichment of BRD2-4 in untreated cells although at lower levels than at the IgH1 enhancer (Fig 3) . However, in contrast to the IgH1 enhancer, BRD2-4
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occupancy did not change in response to I-BET151 suggesting that BRD2-4 binding at the promoter of HEXIM1 is insensitive to I-BET151 (Fig 5D) . However, cyclohexamide treatment had no significant effect on I-BET-mediated increase in HEXIM1 mRNA levels, suggesting that HEXIM1 mRNA upregulation is a direct consequence of I-BET151 treatment (Suppl Fig   3C) .
Taken together, these data show that HEXIM1 overexpression in response to I-BET151 is independent of BRD2-4 but leads to reduced availability of the active form of P-TEFb that is responsible for transcriptional initiation and elongation.
In vitro and in vivo anti-myeloma activity of oral I-BET762
The preclinical tool compound I-BET151 has previously been shown to have anti-leukaemia activity 11 and our data shows that it is also active against myeloma. Based on these observations, we then tested the anti-myeloma activity of I-BET762, a compound with a similar pharmacological profile to I-BET151 but with suitable properties for clinical (Table 1 ).
Next, we tested the anti-myeloma activity of I-BET762 dosed orally in an in vivo systemic xenograft model generated by injecting OPM-2 cells into NOD-SCID mice. Daily oral doses of I-BET762 up to 10 mg/Kg, and 30 mg/Kg given every other day, were well tolerated with no clear impact on body weight as compared to vehicle control (Fig 6B) . We found that plasma hLC concentration was significantly reduced in mice treated with of I-BET762 ( Fig   6C) . Specifically, as disease progressed, hLC concentration in the blood of myeloma-bearing mice increased precipitously. As expected, in vehicle-treated animals, levels of hLC continued to increase until the termination, consistent with progressive myeloma. Although an increase in hLC levels was found in mice treated with I-BET762, mice treated with the 3 highest doses showed a significant reduction (p≤0.001) in the hLC concentration at all 4 time points studied (Fig 6C) . Human CD38+ BM cells in vehicle-treated animals were 10%, while in animals treated with the 3 highest doses was <1% (p≤0.001) (Fig 6D and Suppl Fig 4A) .
Similarly, histopathological analysis of vertebrae at sacrifice shows significantly lower OPM-2 cells infiltration in I-BET762 treated animals (Suppl Fig 4B) . This considerable anti-myeloma activity resulted in a significant (p≤0.002) survival advantage observed in all 4 I-BET762-treated groups of mice, with median survival not reached in animals treated with the 3 highest doses of I-BET762 (Fig 6E) , notably, including the 20-30 mg/Kg daily group that had a dosing holiday during the study and the 30 mg/kg group dosed every other day (Fig 6E) . These data represent the first example of an orally active BET inhibitor significantly delaying myeloma progression in vivo.
DISCUSSION
This study provides mechanistic insight and extended preclinical evidence that I-BET151 and I-BET762, representing the quinoline and benzodiazepine class of BET inhibitors respectively, possess considerable anti-myeloma activity in vitro and in vivo. I-BET151 and 762 constitute novel small molecules that interfere with the ability of the BET family of epigenetic 'readers' to modulate transcription 12 . JQ1 was previously shown to exert antimyeloma activity through cell cycle inhibition and senescence but not apoptosis 14 . We found that similar to JQ1, both I-BET151 and 762 also induce cell cycle arrest and thus exert a potent anti-proliferative effect against myeloma. In addition, they have a clear pro-apoptotic effect, as previously described against acute myeloid leukaemia cells and linked to downregulation of the pro-survival factor BCL2 11 , also observed in both myeloma cell lines treated with I-BET151 (data not shown).
Downregulation of MYC transcription and of the MYC oncogenic programmes have been
shown to be important pathways mediating the anti-proliferative effect of BET inhibitors in many hematologic malignancies including in animal models of myeloma treated with JQ1 35 .
In GEP data analysis previously reported for JQ1 14, 15 , all cell lines were considered together in two homogeneous groups, i.e., before and after treatment with JQ1. To capture the overlapping but also distinct oncogenic programmes that reflect the distinct myeloma initiating genetic events 23 we analysed our GEP data separately for each cell line. Through A consistent feature of all BET inhibitors is their ability to induce in different hematologic tumors, including myeloma 14, 15 over-expression of HEXIM1, a negative regulator of pTEFb [30] [31] [32] . HEXIM1 is part of a ribonucleoprotein complex that consists of cyclin T1/2, CDK9 and small nuclear RNA 7SK (snRNP7SK) which comprise the catalytically inactive form of pTEFb [30] [31] [32] 36 . By contrast, catalytically active P-TEFb requires dissociation from HEXIM1 and its recruitment via BRD4 or transcription factors to the target genes where, through CDK9-dependent Ser2 phosphorylation of the carboxyterminal domain of RNA Pol II, it promotes transcriptional activation and elongation [30] [31] [32] 36 .
Our biochemical dissection of the equilibrium of active versus inactive P-TEFb suggests, that at least in H929 cells, availability of active CDK9 eventually decreases in response to I- , it is significant that the I-BET151 IC50 was not affected by the presence of stroma in most cell lines. The potent anti-myeloma activity of I-BET151 was also apparent in stroma-dependent cultures of primary myeloma cells even in the presence of IL-6, a growth factor that is essential for myeloma survival in vivo [40] [41] [42] . Pertinent to this, IL6R mRNA levels were significantly decreased in both myeloma cell lines in response to I-BET151 (data not shown).
Finally, we demonstrate that a significant survival advantage is gained by I-BET762 in the treatment of established, systemic myeloma in mice, consistent with its in vitro anti-myeloma activity. These data provide the first evidence that I-BET762 13 , currently in phase I studies in solid tumors 43 , has considerable preclinical anti-myeloma activity. Importantly this drug-like small molecule with good oral pharmacokinetics (Suppl Table 2 
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In conclusion, we showed that the tool compound I-BET151, and the structurally distinct clinical candidate I-BET762, demonstrate significant pre-clinical anti-myeloma activity associated with contrasting effects on MYC and HEXIM1 transcription. Our data provide clear rationale for extending the clinical evaluation of the novel therapeutic agent I-BET762 in multiple myeloma.
For 
TABLES
personal use only. on April 3, 2017. by guest www.bloodjournal.org From
